Perspective Therapeutics (CATX) Return on Capital Employed (2011 - 2026)
Perspective Therapeutics (CATX) posted Return on Capital Employed of 1026.22% for Q1 2026, down 18.11% sequentially from 1253.22% in Q4 2025, and up 105713.0% YoY from N/an in Q1 2025.
Perspective Therapeutics (CATX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Perspective Therapeutics has reported Return on Capital Employed for 15 years, with the latest figure at 1026.22% in Q1 2026.
- Quarterly Return on Capital Employed rose 105713.0% year-over-year to 1026.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1026.22% (up 105713.0% YoY) and the FY2025 annual result came in at 41.24%, up 391.0% from the prior year.
- Return on Capital Employed eased to 1026.22% in Q1 2026 per CATX's latest filing, from 1253.22% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 1253.22% in Q4 2025 and troughed at 46.24% in Q4 2023.
- A 5-year average of 110.5% and a median of 26.12% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed plunged 2673 bps in 2022, then surged 127935 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 31.77% in 2022, then tumbled by 46 bps to 46.24% in 2023, then surged by 44 bps to 26.12% in 2024, then soared by 4897 bps to 1253.22% in 2025, then retreated by 18 bps to 1026.22% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 1026.22%, 1253.22%, and 39.26% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 7.98% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 13.69% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 10.83% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 11.99% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 27.21% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 9.47% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 12.84% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 12.08% |
| 10 | Perspective Therapeutics | 389.10 Mn | 389.10 Mn | - | -33.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 862.00% |
| Mar 31, 2026 | 1,026.22% |
| Dec 31, 2025 | 1,253.22% |
| Sep 30, 2025 | -39.26% |
| Jun 30, 2025 | -34.30% |
| Mar 31, 2025 | -30.91% |
| Dec 31, 2024 | -26.12% |
| Sep 30, 2024 | -15.98% |
| Jun 30, 2024 | -15.15% |
| Mar 31, 2024 | -25.45% |
| Dec 31, 2023 | -46.24% |
| Sep 30, 2023 | -32.54% |
| Jun 30, 2023 | -28.47% |
| Mar 31, 2023 | -30.99% |
| Dec 31, 2022 | -31.77% |
| Sep 30, 2022 | -23.84% |
| Jun 30, 2022 | -13.91% |
| Mar 31, 2022 | -6.09% |
| Dec 31, 2021 | -5.03% |
| Sep 30, 2021 | -3.79% |